AndroGel Testosterone Lawsuit: The Heart Attack and Stroke Claims

What the Lawsuits Alleged

AndroGel, made by AbbVie, is a testosterone-replacement therapy. Lawsuits alleged that it and similar products caused cardiovascular harm — heart attacks, strokes and blood clots — and that manufacturers aggressively marketed testosterone for age-related “low T” symptoms in men who did not have a genuine medical deficiency, downplaying the risks. The combination of alleged injury and alleged over-promotion drove the litigation.

This is a classic pharmaceutical failure-to-warn and off-label-marketing theory.

The MDL, Verdicts and Settlements

The cases were consolidated in a large multidistrict litigation (MDL 2545) that at its peak held more than 25,000 lawsuits against several manufacturers. Early trials produced verdicts totaling hundreds of millions of dollars for individual plaintiffs who had heart attacks, and AbbVie — the last major defendant to do so — reached a settlement resolving thousands of AndroGel cases in 2018 (the amount was not disclosed). The product’s label now warns of cardiovascular risk.

The litigation is largely historical, but it remains a reference point for drug-marketing cases.

What Patients Should Know

The broad legal wave has largely resolved; this is not an open sign-up class action. The lasting takeaway for patients is the caution the label now reflects — testosterone therapy carries cardiovascular considerations and is appropriate for a diagnosed deficiency, a decision for a physician rather than a marketing campaign.